Theragenics® Signs Brachytherapy Loading Services Agreement With ONCURA, a Unit of GE Healthcare
12/13/2012 9:43:39 AM
BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it has signed a value-added loading services agreement with Oncura, a unit of GE Healthcare, to provide worldwide brachytherapy loading services to Oncura. Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations. Oncura’s iodine-125 brachytherapy seeds are utilized primarily in the treatment of early stage prostate cancer. This agreement provides for loading services for most Oncura sales of prescription and custom loaded brachytherapy seeds worldwide, which currently includes North America, Europe, Australia and portions of Asia. Theragenics has manufactured radioactive seeds used for the treatment of prostate cancer since 1988 and has performed prescription loading and custom stranding on its internally manufactured brachytherapy seeds since 2005. Theragenics’ brachytherapy products, including needle loaded and custom stranded packaging, are registered in the United States, Canada and Europe. Theragenics is an ISO 13485 certified medical device manufacturer and provides 100% NIST traceable assay. In addition, Theragenics has been Oncura’s exclusive palladium-103 brachytherapy seed supplier since December 2009, providing TheraSeed® for Oncura in prescription loaded and custom stranded configurations.